ViewsML Technologies
New York, United States· Est.
AI-powered virtual IHC platform that delivers rapid, cost‑effective biomarker analysis for oncology and precision medicine.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI-powered virtual IHC platform that delivers rapid, cost‑effective biomarker analysis for oncology and precision medicine.
Oncology
Technology Platform
Deep‑learning models trained on paired H&E and IHC slides generate virtual immunohistochemical stains, providing quantitative, spatial biomarker maps from a single routine slide.
Opportunities
Expansion into additional therapeutic areas, FDA clearance for companion‑diagnostic assays, and scaling through large pathology lab and pharma partnerships.
Risk Factors
Regulatory hurdles for virtual staining as a diagnostic, reliance on high‑quality training data, and competition from established digital pathology vendors.
Competitive Landscape
Competitors include traditional IHC service providers and emerging AI pathology platforms (e.g., PathAI, Paige), but ViewsML differentiates through its ability to generate multiplexed virtual stains from a single H&E slide, dramatically reducing cost and tissue consumption.